Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.

Neoplasia · 2014 · PMC4212250 · PMID 25379022

Europe PMC DOI

hedged sentences

0.0540

closest p · 1.1× alpha

0.0540

boldest claim

The sentences

borderline significanceP = .054so close (0.05 < p ≤ 0.1)

Association of Clinicopathologic Parameters with pCR In the multivariable analysis, CEP17 duplication associated with a high percentage of pCR [odds ratio (OR) 6.55, 95% CI 1.25-34.29, P = .026] and TOP2A gene amplification showed a benefit with borderline significance (OR 6.97, 95% CI 0.96-50.12, P = .054; Table 3 ).

also in 4,352 other papers

showed a trendP = .054so close (0.05 < p ≤ 0.1)

CEP17 duplication correlated with a higher rate of pCR [odds ratio (OR) 6.55, 95% confidence interval (95% CI) 1.25-34.29, P = .026], and analysis of TOP2A amplification showed a trend bordering on statistical significance (OR 6.97, 95% CI 0.96-50.12, P = .054).

also in 33,481 other papers

of borderline significanceP = .054so close (0.05 < p ≤ 0.1)

However, the response was of borderline significance (OR 6.97, 95% CI 0.96-50.12, P = .054), but when combined with CEP17 duplication, the pCR response was significant (OR 6.71, 95% CI 1.66-27.01, P = .007).

also in 1,681 other papers

borderline non-significantP = .054so close (0.05 < p ≤ 0.1)

However, when TOP2A amplification and CEP17 duplication were combined, Kaplan-Meier and log-rank analyses showed a significant association with better DFS ( P = .026) and a borderline non-significant trend with OS ( P = .054; Figure 1 ).

also in 287 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.